ValloVax / Batu Biologics - LARVOL DELTA

Therapeutic Solutions International Spin-Off Res Nova Bio Leverages FDA Cleared Tumor Blood Vessel Targeting Technology to Intravenously Deliver Cancer Killing Viruses (Businesswire) - "Therapeutic Solutions International (TSOI) announced today its Spin-Off Company, Res Nova Bio, achieved successful delivery of a cancer killing virus to breast cancer, resulting in shrinkage of the tumor without induction of side effects. The Company, which is currently manufacturing the FDA-cleared ValloVax endothelial cell vaccine, has demonstrated that intravenous administration of viral infected ValloVax cells results in direct delivery to the breast cancer, causing regression and generation of immunity. The company plans to generate 'next generation' tumor targeting cell therapies based on specific properties of the blood vessels that feed the cancer."

Preclinical • Breast Cancer • Oncology • Solid Tumor

Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy (Businesswire) - "Therapeutic Solutions International (TSOI) announced today that its breast cancer focused spin-off, Res Nova Bio, Inc., initiated a collaboration with Veltmeyer MD Inc. aimed at providing access to the anti-angiogenic immunotherapy ValloVax...There are several peer reviewed publications supporting the use of ValloVax: a) Proof of concept that the ValloVax immunotherapy inhibits tumor growth in various animal models of cancer (lung cancer, melanoma, and breast cancer)..."

Licensing / partnership • Preclinical • Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor